Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | KDM5C | P41229 | 3/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.35 |
| ▸ | KDM6B | O15054 | 2/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3381932 | 0.92 | — | — | |
| SCHEMBL3379761 | 0.76 | — | — | |
| SCHEMBL14545890 | 0.74 | — | — | |
| SCHEMBL372593 | 0.72 | TSHR (0.60) | LMNATSHRSLC22A6NFKB1PMP22 | |
| SCHEMBL11811606 | 0.72 | TSHR (0.60) | LMNATSHRSLC22A6NFKB1PMP22 | |
| SCHEMBL1191720 | 0.68 | LMNA (0.40) | LMNAEGLN1ALKBH5SUCNR1TSHR | |
| SCHEMBL109879 | 0.67 | LMNA (0.53) | LMNAEGLN1ALKBH5SUCNR1TSHR | |
| SCHEMBL16360052 | 0.67 | LMNA (0.53) | LMNAEGLN1ALKBH5SUCNR1TSHR | |
| SCHEMBL5035377 | 0.65 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1TSHR | |
| SCHEMBL17433002 | 0.65 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227201-A1 | Antimicrobial Gel Formulations | NOVABAY PHARMACEUTICALS, INC. | 2014-08-14 | — | — | US | claimed |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | NOVABAY PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | claimed |
| EP-2265267-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NovaBay Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | claimed |
| US-20100272783-A1 | Methods of Treating Infections of the Nail | NOVABAY PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | claimed |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | claimed |
| US-20100010456-A1 | System and Method for the Prevention of Bacterial and Fungal Infections Including Urinary Tract Infection (UTI) Using N-Halogenated Amino Acids | NOVACAL PHARMACEUTICALS, INC. | 2010-01-14 | — | — | US | claimed |
| WO-2009126912-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | claimed |
| EP-2265267-B1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | GOTTARDI WALDEMAR (AT) | 2016-09-21 | — | — | EP | disclosed |
| US-20140227201-A1 | Antimicrobial Gel Formulations | NOVABAY PHARMACEUTICALS, INC. | 2014-08-14 | — | — | US | disclosed |
| US-20120282351-A1 | System and Method for The Prevention of Bacterial and Fungal Infections Including Urinary Tract Infections (UTI) Using N-Halogenated Amino Acids | NOVABAY PHARMACEUTICALS, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | NOVABAY PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | disclosed |
| EP-2312939-A1 | ANTIMICROBIAL GEL FORMULATIONS | NovaBay Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-7846971-B2 | N-halogenated amino acids, N,N-dihalogenated amino acids and derivatives; compositions and methods of using them | NOVABAY PHARMACEUTICALS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20100010456-A1 | System and Method for the Prevention of Bacterial and Fungal Infections Including Urinary Tract Infection (UTI) Using N-Halogenated Amino Acids | NOVACAL PHARMACEUTICALS, INC. | 2010-01-14 | — | — | US | disclosed |
| EP-1948154-A1 | SYSTEM AND METHOD FOR THE PREVENTION OF BACTERIAL AND FUNGAL INFECTIONS INCLUDING URINARY TRACT INFECTIONS (UTI) USING N-HALOGENATED AMINO ACIDS | Novabay Pharmaceuticals, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1896001-A1 | N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDS | Novabay Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070244449-A1 | System and method for the prevention of bacterial and fungal infections including Urinary Tract Infections (UTI) using N-halogenated amino acids | NOVACAL PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | disclosed |
| WO-2007044559-A1 | SYSTEM AND METHOD FOR THE PREVENTION OF BACTERIAL AND FUNGAL INFECTIONS INCLUDING URINARY TRACT INFECTIONS (UTI) USING N-HALOGENATED AMINO ACIDS | NOVABAY PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20060247209-A1 | N-halogenated amino acids, N,N-dihalogenated amino acids and derivatives; compositions and methods of using them | NOVABAY PHARMACEUTICALS, INC. | 2006-11-02 | — | — | US | disclosed |
| WO-2006081392-A1 | N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDS | NOVABAY PHARMACEUTICALS, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272783-A1 | Methods of Treating Infections of the Nail | POLR1C, TYR, NACA | LMNA 3446/4885EGLN1 339/4885ALKBH5 1216/4885 |
| US-20140227201-A1 | Antimicrobial Gel Formulations | CUTA, TUBA3C, POLR1C | LMNA 3899/4885EGLN1 524/4885ALKBH5 3355/4885 |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | CFTR, NAT1, ELANE | LMNA 2673/4885EGLN1 500/4885ALKBH5 647/4885 |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | CUTA, TUBA3C, POLR1C | LMNA 3899/4885EGLN1 524/4885ALKBH5 3355/4885 |
| US-20060247209-A1 | N-halogenated amino acids, N,N-dihalogenated amino acids and derivatives; compositions and methods of using them | DAO, ASNS, DDC | LMNA 3988/4885EGLN1 654/4885ALKBH5 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.